ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 723.27K shares, a 203.62% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 655.79K shares, a 25.69% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.00M shares, a 2550.48% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 273.43K shares, a 1267.14% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.40M shares, a 2210.85% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 103.80K shares, a 77.93% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 470.40K shares, a 66.55% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.41M shares, a 61.72% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 723.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 2.66M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 655.79K shares 10-Q · filed 2026-05-05 | 2.17M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 1.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 2.40M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 273.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.43M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 238.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 1.18M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 882.49K shares 10-Q · filed 2025-05-01 | 955.39K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 37.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 103.80K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 168.90K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 168.90K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 30.90K shares 10-Q · filed 2024-05-07 | 355.55K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 103.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 470.40K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 412.01K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 201.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 523.82K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 145.76K shares 10-Q · filed 2023-05-03 | 904.05K shares derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | 44.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | 1.41M shares 10-K · filed 2023-02-14 |
| 2022-09-30 | 131.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 1.73M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 581.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 1.95M shares derived: sum of 4 quarters · filed 2022-08-03 |
| 2022-03-31 | 648.21K shares 10-Q · filed 2022-05-04 | 2.14M shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 363.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 3.67M shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 360.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 4.57M shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 766.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 5.16M shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 2.18M shares 10-Q · filed 2021-05-05 | 6.01M shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 1.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | 5.20M shares 10-K · filed 2021-02-24 |
| 2020-09-30 | 958.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 4.86M shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 1.61M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | |
| 2020-03-31 | 1.38M shares 10-Q · filed 2020-05-12 | |
| 2019-12-31 | 913.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | 2.29M shares 10-K · filed 2020-02-26 |
| 2018-12-31 | 766.87K shares 10-K · filed 2020-02-26 | |
| 2017-12-31 | 226.21K shares 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |